USB-C is everywhere in 2025. If you've felt like every new device you buy, from smartphones to laptops and tablets, uses a USB-C port for charging, you're not imagining things. USB-C has quickly ...

Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S. at a reduced cash price. This move comes as part of a broader response ...

Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...

On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha. In the late-stage Vesalius-CV study, ...

Matthew Herper covers medical innovation — both its promise and its perils. Amgen said Thursday that its cholesterol-lowering shot, Repatha, prevented a composite of heart disease death, heart attack, ...

Authorities around the world can use your cell phone to track your location and potentially access other sensitive private information about you. One possible protection from this data collection is a ...

Kerstin Wolff and Tobias Matschke of Maiwald Intellectual Property examine a landmark Unified Patent Court decision on second medical use claims and compare it with Germany’s established approach to ...

Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

(RTTNews) - Amgen (AMGN) announced the FDA has broadened the approved use of Repatha or evolocumab to include adults at increased risk for major adverse cardiovascular events due to uncontrolled ...